NOTICE PAPER NO. 1085
NOTICE OF QUESTION FOR WRITTEN ANSWER
FOR THE SITTING OF PARLIAMENT ON 4 APRIL 2022
Name and Constituency of Member of Parliament
Dr Shahira Abdullah
Nominated Member of Parliament
Question No. 1725
To ask the Minister for Health (a) whether there has been an increase in the number of reported incidents of food-related anaphylaxis in children; and (b) whether the Ministry will consider subsidising the costs of EpiPens for low-income families as anaphylaxis can be fatal.
The number of inpatient admissions associated with food-related anaphylaxis amongst patients aged 18 and below, has increased from 49 in 2016 to 111 in 2020.
Today, epinephrine injection drawn from vials or ampoules administered by physicians to patients who experience anaphylaxis is subsidised in public healthcare institutions. EpiPen is a brand of portable epinephrine auto-injector that individuals carry with them, in case of exposure to food or substances they are allergic to. It does not currently qualify for drug subsidies. Patients who face difficulty in affording treatment should approach the Medical Social Workers at the public healthcare institutions for further specific assistance.